What are biosimilars? The Skidki-na-vse® Biosimilars resource center keeps those in the space up to date with the latest clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.

What can we help you find?
First Oncology Biosimilars Launched in United States
The first oncology therapeutic biosimilars are now available in the United States.
Study Shows Similar Efficacy, Safety of Humira Biosimilar
Amgen’s ABP 501 (Amjevita) shows similar efficacy to the reference adalimumab (Humira) in treating rheumatoid arthritis and supported approval of the biosimilar by the FDA.
Class Action Lawsuit Filed Against AbbVie, Biosimilar Manufacturers
Lawsuit alleges that patients paid artificially high prices for brand-name Humira, and that they were deprived of the benefits of early, robust competition from biosimilars as a result of wrongful conduct.
Rheumatoid Arthritis Biosimilar Meets Equivalency Endpoints in Phase 1/3 Trial
Rituximab is approved by the FDA for the treatment of adults with rheumatoid arthritis, non-Hodgkin's lymphoma, chronic lymphocytic leukemia, pemphigus vulgaris, granulomatosis with polyangiitis and microscopic polyangiitis.
Will Biosimilars be the Future of Specialty Pharmacy?
Biosimilars present a cost-saving opportunity for the health care system, but significant challenges inhibit uptake in the US market.
Pharmacists Play Key Role in Driving Utilization of Oncology Biosimilars
As biosimilar development continues to grow, pharmacists will be essential in transitioning both clinicians and patients alike in the use of these therapies.
How Can Pharmacists Approach Reimbursement Challenges to Improve Biosimilar Use?
At the 2018 ASHP Midyear Clinical Meeting and Exhibition, Ashley Mains Espinosa, PharmD, Director of System Pharmacy Business Services at SCL Health, offered advice on how pharmacy providers can work to overcome biosimilar reimbursement challenges and encourage biosimilar adoption.
Phase 3 Studies Show Efficacy of Sandoz Biosimilars Adalimumab, Etanercept
Biosimilars adalimumab and etanercept showed equivalent safety and efficacy to reference products in patients with rheumatoid arthritis.
Biosimilars Action Plan: There's No Better Time Than Now
Several hurdles remain for biosimilars to flourish in the US market.
Innovations and New Approaches for Biological Drugs
Presenters delved into the topic of biological drugs and gene therapy during the recent International Pharmaceutical Federation (FIP) World Congress in Glasgow Scotland.
How Could Biosimilars Change the Specialty Drug Landscape?
Achilles Alon, PharmD, RPh, director of Specialty Pharmacy, co-owner of ACE-Rx Specialty Pharmacy, discusses biosimilars and the potential impact on patient care.
FDA Biosimilar Plan Offers Employers Saving Strategy Solution
Based on 2017 FDA research, the delayed market launch of nine biosimilars represented $4.5 billion in potential savings.
+ Load More